OligoDOMTM: a T-cell response-enhancing platform applied to cancer immunotherapy

OligoDOMTM: a T-cell response-enhancing platform applied to cancer immunotherapy

BackgroundNeoepitopes derived (0) from tumors are attractive cancer immunotherapy targets, especially when combined with immune checkpoint inhibitors (CPIs). Vaccines using lipid nanoparticle (LNP)-encapsulated mRNA to deliver neoepitopes have shown encouraging results in patients and animal models,...

Full description

Saved in:
Bibliographic Details
Main Authors: Judith Del Campo, Séverine Valsesia, Elsa Nikly, Roberto Ruiu, Antonella Iacoviello, Elena Quaglino, Federica Cavallo, Dalil Hannani, Emilie Boucher, Florence Nicolas, Alexandre Le Vert, Francesco Doro
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Immunology
Subjects:
immunotherapy
cancer
t cells
mRNA
nanoparticles
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1549112/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1549112/full

Similar Items